<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03261908</url>
  </required_header>
  <id_info>
    <org_study_id>2016[1237]</org_study_id>
    <nct_id>NCT03261908</nct_id>
  </id_info>
  <brief_title>A Pharmacogenomics Study of Simvastatin-Induced Adverse Drug Reaction</brief_title>
  <official_title>A Pharmacogenomics Study of Simvastatin-Induced Adverse Drug Reaction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cui Yimin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adverse reactions of simvastatin are mostly slight and transient, however, the incidence of
      simvastatin-induced hepatic impairment and myopathy are obviously higher in Chinese
      population than other racial groups. There is still lack of research data in Chinese. In this
      study, we will investigate whether there are specific genotypes which may predict the
      incidence of simvastatin-induced hepatic impairment and myopathy in Chinese so as to provide
      a basis for developing guidelines on precise medication in simvastatin therapy apply to
      Chinese population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of hepatic impairment</measure>
    <time_frame>At 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of myopathy</measure>
    <time_frame>At 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotype detected by next generation sequencing</measure>
    <time_frame>pre-dose of simvastatin(Baseline)</time_frame>
    <description>Collect blood specimen before simvastatin administration, then detect genotype of simvastatin by next generation sequencing.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Simvastatin Adverse Reaction</condition>
  <condition>Pharmacogenomics</condition>
  <condition>Accurate Medication</condition>
  <arm_group>
    <arm_group_label>wild genotype</arm_group_label>
    <description>Through next generation sequencing, distinguish wild genotype of simvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mutant genotype</arm_group_label>
    <description>Through next generation sequencing, distinguish mutant genotype of simvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>detection of genotype</intervention_name>
    <description>detection of genotype by next generation sequencing</description>
    <arm_group_label>wild genotype</arm_group_label>
    <arm_group_label>mutant genotype</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese Patients:In accordance with anti-hyperlipemia indications of simvastatin
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients taking simvastatin therapy

          -  Signed informed consent.

        Exclusion Criteria:

          -  Patients not taking simvastatin therapy

          -  Intolerance or unwillingness to blood sample collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qian Xiang, Ph.D</last_name>
    <phone>+86 010 66110802</phone>
    <email>xiangqz@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Xiang, Ph.D</last_name>
      <phone>+86 010 66110802</phone>
      <email>xiangqz@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Cui Yimin</investigator_full_name>
    <investigator_title>Director of pharmacyï¼ŒM.D &amp; Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

